Live thread

Daraxonrasib — new drug doubles survival time in metastatic pancreatic cancer

Three days after the first headlines about Daraxonrasib, the expert community is discussing new treatment approaches for pancreatic cancer intensively at ASCO, the world's largest cancer congress — and debating which barriers still separate patients from access to such therapies.

This story is part of Kirla. Sign in to read the full coverage.

Sign in to read